|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000744,
umls-concept:C0021201,
umls-concept:C0023473,
umls-concept:C0026882,
umls-concept:C0031727,
umls-concept:C0080279,
umls-concept:C0683598,
umls-concept:C0868928,
umls-concept:C0936012,
umls-concept:C1268567,
umls-concept:C1412097,
umls-concept:C1514562,
umls-concept:C1826328,
umls-concept:C1880389,
umls-concept:C1883204,
umls-concept:C1883221,
umls-concept:C2266681,
umls-concept:C2757011
|
|
pubmed:issue |
7-8
|
|
pubmed:dateCreated |
2011-9-5
|
|
pubmed:abstractText |
The current study was undertaken to find out the frequency and distribution of ABL kinase domain (KD) mutations showing resistance to tyrosine kinase inhibitors (TKI) in CML patients from India.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/abl-bcr fusion protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/dasatinib,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1433-6510
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
619-23
|
|
pubmed:meshHeading |
pubmed-meshheading:21888027-Adult,
pubmed-meshheading:21888027-Aged,
pubmed-meshheading:21888027-Antineoplastic Agents,
pubmed-meshheading:21888027-Binding Sites,
pubmed-meshheading:21888027-Blast Crisis,
pubmed-meshheading:21888027-Catalytic Domain,
pubmed-meshheading:21888027-DNA, Neoplasm,
pubmed-meshheading:21888027-Drug Resistance, Multiple,
pubmed-meshheading:21888027-Drug Resistance, Neoplasm,
pubmed-meshheading:21888027-Female,
pubmed-meshheading:21888027-Fusion Proteins, bcr-abl,
pubmed-meshheading:21888027-Gene Frequency,
pubmed-meshheading:21888027-Genes, abl,
pubmed-meshheading:21888027-Humans,
pubmed-meshheading:21888027-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:21888027-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:21888027-Male,
pubmed-meshheading:21888027-Middle Aged,
pubmed-meshheading:21888027-Mutation, Missense,
pubmed-meshheading:21888027-Piperazines,
pubmed-meshheading:21888027-Point Mutation,
pubmed-meshheading:21888027-Protein Kinase Inhibitors,
pubmed-meshheading:21888027-Protein Structure, Tertiary,
pubmed-meshheading:21888027-Pyrimidines,
pubmed-meshheading:21888027-Thiazoles
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
|
|
pubmed:affiliation |
Research and Development, Super Religare Laboratories, Mumbai, India.
|
|
pubmed:publicationType |
Journal Article
|
